Human Genetic Therapies Boosts Shire, Thanks To Replagal Growth
This article was originally published in The Pink Sheet Daily
Executive Summary
Genzyme's inability to provide Fabry disease patients with Fabrazyme has created an opening for Replagal, whose half-year sales are up 77 percent year-over-year.
You may also be interested in...
Shire's Strong 2010 Performance Helped By Huge Sales Growth In HGT Business
Continuing to capitalize on supply problems plaguing rival Genzyme, Shire reported 81% year-over-year sales growth for Fabry disease drug Replagal.
Shire's Strong 2010 Performance Helped By Huge Sales Growth In HGT Business
Continuing to capitalize on supply problems plaguing rival Genzyme, Shire reported 81% year-over-year sales growth for Fabry disease drug Replagal.
Shire Emphasizes The GI Space In Its Bid For Movetis
Only five years ago, Shire's specialty pharma business consisted of one product, Adderall XR, one market, the U.S., and one patient type - children. Multiple generics companies had filed ANDAs, however, and the company was looking to broaden its base